Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognizing its innovative approach to addressing cancer drug resistance. The award underscores the company's strategy centered on resistance-modulating treatments, particularly its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies.
Kairos Pharma is advancing combination approaches aimed at improving the durability of response across multiple cancer indications. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is being evaluated in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The recognition from the Pinnacle Awards highlights Kairos Pharma's commitment to overcoming one of the biggest challenges in oncology: drug resistance. The company's approach leverages structural biology to overcome drug resistance and immune suppression in cancer, positioning it at the forefront of oncology therapeutics.
For more information about Kairos Pharma, visit its newsroom at https://ibn.fm/KAPA. The full press release is available at https://ibn.fm/ghPJC.
